WO1998047872A1 - Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a - Google Patents
Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a Download PDFInfo
- Publication number
- WO1998047872A1 WO1998047872A1 PCT/EP1998/002118 EP9802118W WO9847872A1 WO 1998047872 A1 WO1998047872 A1 WO 1998047872A1 EP 9802118 W EP9802118 W EP 9802118W WO 9847872 A1 WO9847872 A1 WO 9847872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flupirtine
- maleate
- modification
- pure
- base
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the present invention relates to a process for the production of pure flupirtine maleate and the pure crystal modification A of flupirtine maleate.
- Flupirtine maleate is 2-amino-3-carbethoxyamino-6- (p-fluoro-benzylamine) - py ⁇ din maleate (I). This compound is commercially available under the brand name Katadolon® and is used in particular as an analgesic
- crude flupirtine maleate is converted into raw flupirtine base by release with ammonia or sodium hydroxide solution.
- This release process produces ammonium or sodium salts which are wastewater-polluting and which are a disturbing side effect from an ecological point of view.
- the raw flupirtine base is made from isopropanol re-installed and after clarification of activated carbon / diatomaceous earth with an isopropanolic maleic acid solution converted to pure flupirtine maleate
- reaction steps C - E are required purification steps, without which no pure, uniform and specification-compliant pure maleate could be obtained. They represent very labor-intensive and cost-intensive cleaning operations, considerably lengthen the synthesis process and only lead to a specification-compliant pure flupirtine maleate in a production-technically very complex, complicated and cumbersome way As a further criterion for a technically very high effort with the
- Purification steps C and E apply the extremely large reactor volumes which are required for the crystallization of the flupirtine base and for the precipitation of the flupirtine maleate and which tie up a considerable amount of production capacity
- the flupirtine maleate is generally obtained as a mixture of two constituent modifications A and B, these being present in the mixture in different ratios.
- the object is achieved in that the hydrogenation of 2-amino-3-nitro-6- (4-fluorobenzylamino) pyridine (ANFP) in the presence of Raney nickel, acylation of the intermediate compound 2,3-diamino-6 - (4-fluorobenzylamino) pyridine (DAFP) with ethyl chloroformate and the reaction of the flupirtine base obtained with maleic acid in water-soluble alcohols, such as ethanol or isopropanol.
- ANFP 2-amino-3-nitro-6- (4-fluorobenzylamino) pyridine
- DAFP 2,3-diamino-6 - (4-fluorobenzylamino) pyridine
- the crude base synthesized, dissolved and very oxygen-sensitive in process step A could be converted into an aqueous maleic acid solution by a very rapid suction process, from which the flupirtine crude maleate, which was much less colored than in the past, immediately precipitated out with stirring. After crystallization in isopropanol-water, this gave a pure maleate according to the specification in about 85% yield.
- Process step G represents an even shorter process alternative compared to process step F, in which the flupirtine crude maleate is precipitated from the flupirtine base formed in situ in isopropanol by suction in an aqueous maleic acid solution at 50-60 ° C. and after modification colorless pure flupirtine maleate in
- the flupirtine base is preferably precipitated in ethanol or water and purified by simple recrystallization.
- the flupirtine pure maleate is then produced analogously to the process variants mentioned.
- a further advantage turned out to be the fact that, for the first time, a white product free of color complexes was obtained with the flupirtine crude maleate precipitation, so that here too no additional cleaning operations are required
- the dysentery process will immediately follow the fall, that is to say, starting with the cooling, the stirring will continue even after cooling to room temperature until the conversion is complete.
- the solids concentration will be kept as high as possible
- predried crystals which have been freed from externally adsorbed solvent, but which still contains solvent which is bound in crystalline form, can be converted into modification B by heating to temperatures of about 80-100.degree.
- the subsequent formation of modification B from solvate during technical drying is prevented by stirring the Kristal isuspension for a sufficiently long time after the maleate precipitation.
- the crystallized phases of flupirtine maleate, modification A and B as well as isopropanol and ethanol solvate were determined by X-ray diffraction with a powder diffractometer. With this method one obtains a transformed image of the crystal structure or structures present, which is created by summation of the diffraction effects on a very large number of crystals. This method is therefore particularly suitable for determining the composition of mixtures consisting of different crystallized phases fresh, still solvent-moist samples can be examined. Furthermore, structural changes associated with phase transitions can be observed directly
- Figure 1 shows the diffractograms of Modifications A and B in the lower part
- Table 1 shows the powder data. Both modifications show characteristic reflexes that do not coincide with a reflex of the other modification. In modification A these are in particular the strong reflections at 6.9, 9.2 and 17.9 ° 2 ⁇ and in modification B in particular the strongest reflection at 5.5 ° 2 ⁇ .
- the detection limit for modification B is ⁇ 1% ( Figure 2).
- Table 1 Powder data for the modifications of flupirtine maleate
- Figure 1 shows the two solvates of the flupirtine maleate in the upper part
- the relationship between the diffractograms of the solvates and the diffractogram of modification A suggests that the internal solvent incorporation takes place during the nucleation of modification A.
- Figure 3 shows the DSC curves of the two modifications.
- Modification A shows two endothermic reactions, namely the transition point A -> B at 164 ° C (onset) and the melting point of modification B at 184 ° C (onset).
- Modification B shows only an endothermic effect at 184 ° C, which indicates the melting.
- Figure 4 shows the thermal lattice transformation A -> B.
- the strong reflection of modification B appears at 5.5 ° 2 ⁇ at 165 ° C.
- Figures 5 and 6 show the different course of the crystal reactions during the heating of solvent-moist and pre-dried products using the example of an isopropanol crystal. In the moist state, the desolvation takes place together with the release of the externally bound solvent with the formation of modification A, which then occurs at 164 ° C modification B is converted
- Figure 7 shows the thermal lattice conversions with an isopropanol crystallizate.First, there is solvate (6 4 ° 2 ⁇ ) next to modification A At 95 ° C the characteristic solvate reflex disappears and the characteristic reflex of modification B appears at 5 5 ° 2 ⁇ When heating continues with a strong increase in intensity of the B reflex, the characteristic reflections of the modification A at 6 9 and 9 2 ° 2 ⁇
- process step A the questionable solvent 2-methoxyethanol is replaced by water-soluble alcohols such as isopropanol or ethanol
- 75 g (0.286 mol) of ANFP are hydrogenated in a suspension of 12.5 g of Raney nickel in 400 ml of isopropanol at 65 ° C. and 5 bar hydrogen pressure.
- the solution is mixed with 26.4 ml of ethyl chloroformate and then with 50.6 ml of triethylamine.
- the reaction solution is stirred at 60 ° C. for 1 hour.
- the hot solution is then sucked into a solution of 53.3 g of maleic acid in 1.5 IH 2 O, heated to 50-60 ° C., and the catalyst is washed with a little isopropanol.
- the flupirtine maleate is colorless, the crystal suspension is cooled to 20 ° C. with further stirring and left at this temperature for 20 minutes. It is suctioned off, washed with about 500 ml of water and the flupirtine maleate is dried in vacuo at 35 ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98920511A EP0977736B1 (de) | 1997-04-23 | 1998-04-11 | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a |
JP54494098A JP4960538B2 (ja) | 1997-04-23 | 1998-04-11 | 純フルピルチンマレエート及びその変態aの製造方法 |
AU73346/98A AU7334698A (en) | 1997-04-23 | 1998-04-11 | Process for preparing pure flupirtin maleate and its modification |
DE59809728T DE59809728D1 (de) | 1997-04-23 | 1998-04-11 | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a |
AT98920511T ATE250579T1 (de) | 1997-04-23 | 1998-04-11 | Verfahren zur herstellung von reinem flupirtin- maleat und dessen modifikation a |
DK98920511T DK0977736T3 (da) | 1997-04-23 | 1998-04-11 | Fremgangsmåde til fremstilling af rent flupirtin-maleat og dettes modifikation A |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19716984A DE19716984A1 (de) | 1997-04-23 | 1997-04-23 | Verfahren zur Herstellung von reinem Flupirtin-Maleat und dessen Modifikation A |
DE19716984.8 | 1997-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998047872A1 true WO1998047872A1 (de) | 1998-10-29 |
Family
ID=7827393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/002118 WO1998047872A1 (de) | 1997-04-23 | 1998-04-11 | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a |
Country Status (12)
Country | Link |
---|---|
US (1) | US5959115A (de) |
EP (1) | EP0977736B1 (de) |
JP (1) | JP4960538B2 (de) |
AR (1) | AR012597A1 (de) |
AT (1) | ATE250579T1 (de) |
AU (1) | AU7334698A (de) |
DE (2) | DE19716984A1 (de) |
DK (1) | DK0977736T3 (de) |
ES (1) | ES2207832T3 (de) |
PT (1) | PT977736E (de) |
WO (1) | WO1998047872A1 (de) |
ZA (1) | ZA983376B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110357A1 (en) * | 2007-03-12 | 2008-09-18 | Elbion Gmbh | Method for preparing a flupirtine maleate of a crystal modification b |
WO2010136113A1 (de) * | 2009-05-29 | 2010-12-02 | Corden Pharmachem Gmbh | Verfahren zur herstellung von flupirtin |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821995B1 (en) | 1999-12-01 | 2004-11-23 | Duke University | Method of treating batten disease |
GB0613928D0 (en) * | 2006-07-13 | 2006-08-23 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salt and polymorphic forms |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
WO2009152168A2 (en) | 2008-06-09 | 2009-12-17 | Awd. Pharma Gmbh & Co. Kg | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
EP2350009B1 (de) | 2008-06-09 | 2016-03-16 | TEVA GmbH | Sulfonatsalze von flupirtin |
CN102140077A (zh) * | 2010-01-28 | 2011-08-03 | 范扶民 | 氟吡汀a晶型及其制备方法 |
WO2012004391A1 (en) * | 2010-07-09 | 2012-01-12 | K.H.S. Pharma Holding Gmbh | Process for the preparation of flupirtine maleate |
DE102010063609A1 (de) | 2010-12-20 | 2012-06-21 | Awd.Pharma Gmbh & Co. Kg | Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure |
DE102010063612A1 (de) | 2010-12-20 | 2012-06-21 | Awd.Pharma Gmbh & Co. Kg | Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamidsäureethylester und 2-[2-[(2,6-Dichlorphenyl)-amino]-phenyl]-essigsäure |
CN102351786A (zh) * | 2011-11-01 | 2012-02-15 | 东南大学 | 一种氟吡汀丙二酸盐及其制备方法 |
WO2013080215A1 (en) | 2011-11-30 | 2013-06-06 | Arch Pharmalabs Limited | An improved process for the preparation of flupirtine and pharmaceutically acceptable salts thereof |
DE102015013478A1 (de) | 2015-10-17 | 2017-04-20 | Goethe-Universität | Neue Kristallphasen von Flupirtin-Maleat |
DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3133519A1 (de) * | 1980-09-13 | 1982-06-09 | Degussa Ag, 6000 Frankfurt | "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat" |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481205A (en) * | 1980-09-13 | 1984-11-06 | Degussa Aktiengesellschaft | 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate |
-
1997
- 1997-04-23 DE DE19716984A patent/DE19716984A1/de not_active Withdrawn
-
1998
- 1998-04-11 WO PCT/EP1998/002118 patent/WO1998047872A1/de active IP Right Grant
- 1998-04-11 EP EP98920511A patent/EP0977736B1/de not_active Expired - Lifetime
- 1998-04-11 PT PT98920511T patent/PT977736E/pt unknown
- 1998-04-11 JP JP54494098A patent/JP4960538B2/ja not_active Expired - Fee Related
- 1998-04-11 AU AU73346/98A patent/AU7334698A/en not_active Abandoned
- 1998-04-11 AT AT98920511T patent/ATE250579T1/de active
- 1998-04-11 DE DE59809728T patent/DE59809728D1/de not_active Expired - Lifetime
- 1998-04-11 ES ES98920511T patent/ES2207832T3/es not_active Expired - Lifetime
- 1998-04-11 DK DK98920511T patent/DK0977736T3/da active
- 1998-04-22 ZA ZA9803376A patent/ZA983376B/xx unknown
- 1998-04-23 US US09/064,790 patent/US5959115A/en not_active Expired - Lifetime
- 1998-04-23 AR ARP980101893A patent/AR012597A1/es not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3133519A1 (de) * | 1980-09-13 | 1982-06-09 | Degussa Ag, 6000 Frankfurt | "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat" |
Non-Patent Citations (1)
Title |
---|
S SCHWOCH ET AL.: "2,3-Dihydrospiro[1H-4- and 5-azabenzimidazole-2,1'-cyclohexane]: Reactions with nucleophiles", HELVETICA CHIMICA ACTA., vol. 77, no. 8, 1994, BASEL CH, pages 2175 - 2190, XP002073789 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110357A1 (en) * | 2007-03-12 | 2008-09-18 | Elbion Gmbh | Method for preparing a flupirtine maleate of a crystal modification b |
WO2010136113A1 (de) * | 2009-05-29 | 2010-12-02 | Corden Pharmachem Gmbh | Verfahren zur herstellung von flupirtin |
DE102009023162A1 (de) | 2009-05-29 | 2011-01-13 | Corden Pharmachem Gmbh | Verfahren zur Herstellung von Flupirtin |
DE102009023162B4 (de) * | 2009-05-29 | 2011-07-07 | Corden PharmaChem GmbH, 68305 | Verfahren zur Herstellung von Flupirtin |
Also Published As
Publication number | Publication date |
---|---|
ATE250579T1 (de) | 2003-10-15 |
AR012597A1 (es) | 2000-11-08 |
ZA983376B (en) | 1998-07-03 |
JP2001523236A (ja) | 2001-11-20 |
DK0977736T3 (da) | 2004-01-19 |
AU7334698A (en) | 1998-11-13 |
EP0977736A1 (de) | 2000-02-09 |
ES2207832T3 (es) | 2004-06-01 |
PT977736E (pt) | 2004-02-27 |
DE59809728D1 (de) | 2003-10-30 |
JP4960538B2 (ja) | 2012-06-27 |
US5959115A (en) | 1999-09-28 |
EP0977736B1 (de) | 2003-09-24 |
DE19716984A1 (de) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1660482B1 (de) | 3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel | |
EP0977736B1 (de) | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a | |
DE69922977T2 (de) | Neue Kristallmodifikation von Torasemid | |
DE2147023C3 (de) | Verfahren zur Herstellung von 1H- Tetrazol-Verbindungen | |
DE3133519C2 (de) | ||
EP1404673B1 (de) | Technische syntheseverfahren zur herstellung von tropenol | |
DE1906527B2 (de) | Thioninderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, welche diese enthalten | |
DE60302571T2 (de) | Verfahren zur herstellung der amorphen form von atorvastatin calzium salz | |
DE2828074A1 (de) | Form ii der 2-(4-chlorphenyl)- alpha -methyl-5-benzoxazolyl-essigsaeure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel | |
EP1060177B1 (de) | Verfahren zur herstellung von doxazosin-mesylat in einer als form a bezeichneten kristallmodifikation und ein zwischenprodukt für deren herstellung | |
DE69418953T2 (de) | Kristalle einer antimikrobiellen Verbindung | |
DE102009023162B4 (de) | Verfahren zur Herstellung von Flupirtin | |
DE2022656A1 (de) | Aminoaethansulfonylderivate und Verfahren zu ihrer Herstellung | |
DE2123555C3 (de) | Verfahren zur Herstellung von 21-Desoxy-21-N-(N>-methylpiperazinyl)prednisolon und dessen Salzen | |
EP1116724B1 (de) | Verfahren zur Herstellung von [IrCODCl]2 | |
DE830511C (de) | Verfahren zur Herstellung von neuen diquartaeren Salzen von Pyrimidylaminochinolinen | |
WO2001040229A2 (de) | Verfahren zur herstellung von epinastine-hydrochlorid in der hochschmelzenden kristallmodifikation | |
DE3887376T2 (de) | 2-Methyl-4-amino-5-aminomethylpyrimidinkarbonat, Verfahren zu dessen Herstellung und diese brauchende Methode zur Reinigung von 2-Methyl-4-amino-5-aminomethylpyrimidin. | |
DE825413C (de) | Verfahren zur Herstellung von quartaeren Sulfaten oder Sulfonaten von Pyrimidylaminochinolinen | |
DE2705949A1 (de) | Neue therapeutika auf piperidinbasis | |
DE1568552C3 (de) | N-acylierte 1 -Chlorbenzol-24-disulfonamide und Verfahren zu ihrer Herstellung | |
DE2065698A1 (de) | Verfahren zur herstellung von 2isopropyl-6-methyl-4(3h)-pyrimidon | |
DE850297C (de) | Verfahren zur Herstellung von Amidinsalzen | |
DE825548C (de) | Verfahren zur Herstellung von neuen diquartaeren Salzen von Pyrimidylaminocinnolinen | |
DE2026057C3 (de) | Verfahren zur Herstellung von Metallphthalocyanin in der X-Form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU IS JP NO PL RU SK |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998920511 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 544940 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998920511 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998920511 Country of ref document: EP |